The earnings call reflects a strong positive outlook for Cidara Therapeutics due to successful clinical trial results, significant financial backing, and advancing regulatory discussions. However, challenges remain due to the company's non-revenue generating status and potential delays in Phase III study commencement.

Company Guidance

During the Cidara Therapeutics Second Quarter 2025 earnings call, significant progress was highlighted, particularly with the positive top-line results from the Phase IIb NAVIGATE clinical trial for CD388, which demonstrated 76%, 61%, and 58% protection in three different dose groups. The study enrolled over 5,000 subjects, and the observed placebo attack rate was 2.8%, allowing for statistically significant differences in efficacy with p-values of less than 0.0001, 0.0024, and 0.005 for the respective doses. Following these results, Cidara secured $400 million in financing and engaged in discussions with the FDA and BARDA, with plans to initiate a Phase III study in 2026. The company also emphasized CD388's potential as a universal preventative for influenza, supported by its current Fast Track and Priority Review designations. Cidara aims to target high-risk populations, including immune-compromised patients, in their upcoming Phase III study, backed by their strong financial position from a recent $402.5 million public offering.

Positive Phase IIb NAVIGATE Clinical Trial Results

Cidara Therapeutics announced positive top line results from its Phase IIb NAVIGATE clinical trial, demonstrating statistically significant efficacy of CD388 with 76%, 61%, and 58% protection rates at 450mg, 300mg, and 150mg doses respectively, all with p-values indicating strong statistical significance compared to placebo.

$400 Million Financing Secured

Cidara secured $400 million in financing, providing a strong financial position to fund the completion of the planned Phase III study and additional supportive clinical and nonclinical studies.

Potential FDA and BARDA Support

Cidara advanced discussions with the FDA for Phase III development and submitted a proposal to BARDA which, if funded, could provide significant support for manufacturing and clinical development of CD388.

Fast Track and Priority Review Designations

CD388 has received Fast Track and Priority Review designations from the FDA, and an application for Breakthrough Therapy Designation has been submitted.

Cidara Therapeutics (CDTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CDTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-1.64 / -	-2.45	―	―	―
Aug 07, 2025	2025 (Q2)	-1.94 / -1.65	-19.99	91.75% (+18.34)	―
May 08, 2025	2025 (Q1)	-3.54 / -1.66	-2.28	27.19% (+0.62)	―
Mar 06, 2025	2024 (Q4)	-3.62 / -5.37	-0.8	-571.25% (-4.57)	―	―
Nov 07, 2024	2024 (Q3)	-4.25 / -2.45	-1.8	-36.11% (-0.65)	―	―
Aug 13, 2024	2024 (Q2)	-4.10 / -19.99	-2.8	-613.93% (-17.19)	―	―
May 15, 2024	2024 (Q1)	-2.39 / -2.28	0.6	-480.00% (-2.88)	―	―
Feb 28, 2024	2023 (Q4)	-1.50 / -0.80	-3.8	78.95% (+3.00)	―	―
Nov 02, 2023	2023 (Q3)	-3.00 / -1.80	3.4	-152.94% (-5.20)	―	―
Aug 03, 2023	2023 (Q2)	-2.60 / -2.80	-3.8	26.32% (+1.00)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CDTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$61.73	$62.00	+0.44%
May 08, 2025	$19.15	$18.63	-2.72%
Mar 06, 2025	$23.61	$23.66	+0.21%
Nov 07, 2024	$13.11	$13.50	+2.97%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cidara Therapeutics (CDTX) report earnings?

Cidara Therapeutics (CDTX) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Cidara Therapeutics (CDTX) earnings time?

Cidara Therapeutics (CDTX) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CDTX EPS forecast?

CDTX EPS forecast for the fiscal quarter 2025 (Q3) is -1.64.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing